The present invention covers combinations of at least two components, component A and component B, component A being an ATR kinase inhibitor, and component B being radium-223, particularly a pharmaceutically acceptable salt of radium-223. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a hyper-proliferative disease, particurlarly for the treatment of prostate cancer as well as bone metastases thereof.本發明涵蓋至少兩種組分、組分A及組分B之組合,組分A為ATR激酶抑制劑,及組分B為鐳-223,特別是鐳-223之醫藥學上可接受之鹽。本發明之另一態樣涵蓋如本文中所描述之此類組合之用途,其用於製備用以治療或預防過度增生性疾病,特別是用以治療前列腺癌以及其骨轉移之藥劑。
